(Q35015866)

5 August 2017

1 reference

title

Treatment targeted to cell surface epitopes (English)

1 reference

5 August 2017

Mrowietz U

1

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Clinical and Experimental Dermatology

5 August 2017

published in

1 reference

5 August 2017

volume

27

1 reference

5 August 2017

issue

7

1 reference

5 August 2017

page(s)

591-596

1 reference

Advances in systemic therapy for psoriasis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

CD4 antibody treatment of severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

The inflammatory infiltrate in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Anti-CD4 monoclonal antibody therapy in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Treatment of recalcitrant psoriasis with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01171.X

10.1046/J.1365-2230.2002.01171.X

21 January 2018

Identifiers

DOI

1 reference

release_2dh5dvxu6vcvxotup5xxeplgc4

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2dh5dvxu6vcvxotup5xxeplgc4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference